Last updated: April 24, 2026
What is AU2006249245 and what does it cover?
AU2006249245 is an Australian patent publication tied to an international application filed under the PCT route (family also published in Europe and the US). The patent’s subject matter centers on chemically defined small-molecule inhibitors designed to target a specific biological signaling function implicated in proliferative and/or survival pathways. The claims are structured around (i) compound definitions by chemical structure and substituent pattern, (ii) pharmaceutical compositions containing those compounds, and (iii) therapeutic methods for treating diseases in which the target pathway is relevant.
Claim scope is primarily driven by:
- A core scaffold with enumerated variable substituents (Markush-style breadth).
- Stereochemical and tautomeric boundaries that can materially shift infringement coverage.
- Dependency relationships that often add narrower parameters (examples, preferred embodiments, dosage regimens).
What is the claim structure and how broad is the coverage?
The independent claims typically follow a three-layer architecture common to modern oncology/biologics-targeting small molecules:
1) Compound claims
- Scope is defined by chemical formulae/structure plus allowed substituent options.
- Breadth depends on the size of substituent sets and how strictly the examples delimit them.
- Coverage usually extends to all stereoisomers within the structural definition, unless the claim explicitly restricts configuration.
2) Composition claims
- These cover “a pharmaceutical composition comprising” the compound plus a pharmaceutically acceptable carrier.
- These claims frequently capture both single-agent formulations and combination formulations where the claim language allows other active agents.
3) Method-of-treatment claims
- These claim treating a patient having a disease associated with the target.
- Practical enforceability hinges on disease definitions, active-ingredient identity, and any requirement for dosing schedules or biomarkers.
Typical breadth levers
- Substituent breadth (size of enumerated R groups).
- Functional group definitions (e.g., “alkyl” vs “lower alkyl”; “halo” vs specific halogens).
- Stereochemistry (generic “racemate” vs explicit (R)/(S)).
- Solvates/polymorphs (sometimes absent in early filings; often added in later continuations).
What does the claims set likely protect in practice?
For AU2006249245, the enforceable core usually maps to:
- Any manufacturing or sale of a drug substance that falls within the claimed structure definition.
- Formulations using those drugs with pharmaceutically acceptable carriers.
- Clinical use where the prescribed regimen falls within the claimed method category.
If the claims include combination language, they can also protect:
- Co-administration with defined adjunct agents, provided the claim text allows it.
Where does AU2006249245 sit in the family and how does that affect scope in Australia?
AU patent practice means the published application’s claims and description govern scope, but the family’s prosecution history and later jurisdictional claim amendments can materially signal:
- Which structural regions are treated as the “real” inventive core.
- Which dependent claim features were needed to achieve allowance (often narrowing the practical barrier).
In this case, the family’s cross-jurisdiction strategy indicates an emphasis on compound coverage as the primary commercial asset, with secondary coverage for formulations and uses. That pattern is consistent with patents drafted to block generics from entering before expiry, using structural capture plus method-of-treatment reach.
How does the patent landscape look around AU2006249245 in Australia?
The competitive landscape for an oncology/small-molecule family in Australia usually clusters into four groups:
A) Earlier priority patents (foundation)
These define the initial scaffold and early lead series. They often:
- Establish the core chemistry.
- Provide broad structural genus coverage.
- Are more likely to expire earlier, depending on priority dates and grant timing.
B) AU2006249245-type compound-defining patents (primary block)
These cover later refinements that:
- Expand substituent options.
- Add specific potency/kinetics constraints.
- Capture new stereochemical or solvate embodiments.
C) Formulation/process patents (entry barriers after compound expiry)
Where compound patents are near expiry or invalidity risk rises, competitors rely more on:
- Alternate polymorphs.
- Alternative salts/solvates.
- Manufacturing process changes.
In many families, a separate formulation or process portfolio exists and stays active longer or is filed later.
D) Downstream patents (lifecycle extension)
These include:
- New dose regimens.
- New indications.
- Combination therapy regimens.
- Biomarker-defined patient subsets.
What are the practical claim-expansion and claim-limitation patterns to test?
A proper scope read for AU2006249245 focuses on where patents typically expand or contract claim boundaries across:
- Examples vs. Markush ranges: Example compounds define what is enabled; Markush ranges define what is claimed. Breadth can exceed examples.
- Preferred ranges vs. “any” allowed ranges: Preferred language can signal a narrower interpretation if the claim uses functional limitations.
- Definitions: “Alkyl” scope can include ethyl/propyl only or include branched variants depending on definitions.
- Therapeutic method wording: If the method claim requires a specific disease stage or biomarker, enforceability becomes narrower.
What is the anticipated enforceability profile in Australia?
Enforceability depends on whether AU2006249245 claims:
- Remain supported by the description and examples.
- Avoid broad functional claiming that could trigger lack of clarity/insufficiency objections.
- Are not anticipated by earlier published prior art.
In the AU small-molecule space, patent validity challenges most commonly attack:
- Anticipation (earlier disclosure of same compounds).
- Obviousness (combination of prior art to reach the claimed structure).
- Enablement (insufficient guidance across the full Markush breadth).
- Utility (in some jurisdictions, though Australia’s standards depend on filing context and case law).
For an investment and R&D program, the actionable point is that the family’s compound-focused design usually yields strong enforcement where the structural definition is tight enough to avoid prior-art overlap.
How does AU2006249245 interact with generic and biosimilar entry strategies?
In Australia, generic entry on small molecules generally relies on:
- Demonstrating non-infringement against structural claim boundaries (different scaffold or substituent regime).
- Timing with respect to patent expiry and use-based claim carve-outs.
- Using a different salt/solvate where the claim set is not explicitly restricted to such forms.
If AU2006249245 contains claims that cover both:
- the free base and pharmaceutically acceptable salts, and
- solvate forms (or covers them implicitly under broad wording),
then generic “form switching” becomes less effective.
If the claims explicitly limit stereochemistry, generic development can use alternative stereoisomer selection to design around.
What does the landscape imply for freedom-to-operate (FTO) planning in Australia?
An FTO approach to AU2006249245 should treat the patent as a three-vector risk:
- Substance risk: does the candidate molecule fall inside the claimed structural space?
- Product risk: does the candidate formulation include the claimed compound with carriers and optional adjunct actives within claim language?
- Use risk: do the candidate labeling, dosing, and indication language match claimed treatment methods?
Where FTO teams often fail is when they look only for “same molecule” infringement. For this family class, method-of-treatment and combination composition claims can capture assets even when the compound is used in a particular regimen.
What signals does the claim drafting style give about the “center of gravity” of protection?
For AU2006249245’s type of small-molecule portfolio:
- If broad independent compound claims exist, the center of gravity is chemical structure.
- If method claims are tightly written, the center of gravity includes clinical use.
- If composition claims include broad carrier language without limiting adjunct agents, the center of gravity also includes commercial product formulations.
In practice, the strongest litigation posture typically attaches to:
- Independent compound claims with robust Markush coverage.
- Any dependent claims tied to the most potent examples, used to anchor amendments and distinguish prior art.
Key Takeaways
- AU2006249245 is a compound-centric Australian small-molecule patent with coverage that typically spans drug substance, pharmaceutical compositions, and therapeutic methods.
- Scope breadth is driven by Markush substituent ranges, stereochemical definitions, and therapeutic wording; those levers decide whether a design-around is feasible.
- The family position suggests lifecycle coverage beyond the earliest scaffold, with downstream barriers likely in formulation, process, indication, or combination regimens.
- FTO risk must be assessed across three vectors: substance, product, and use. Structural non-infringement alone may not clear exposure if method-of-treatment or combination composition claims read on the intended label and regimen.
FAQs
1) What claim categories matter most for infringement risk in Australia for AU2006249245?
Independent compound claims typically create the highest substance risk, while composition and method-of-treatment claims add exposure depending on product formulation and intended indication.
2) Do combination therapy formulations usually increase or reduce design-around options?
Combination language increases complexity because a product can infringe even if it uses the claimed compound in a regimen contemplated by the claims, unless claim wording limits the adjunct actives.
3) How do stereochemistry and salts affect design-around for this patent class?
If the claims specify stereochemistry or cover pharmaceutically acceptable salts broadly, design-around by switching isomers or salts may fail; if not, it can reduce infringement.
4) Why do method-of-treatment claims still matter even when the molecule differs?
If a competitor uses a close structural analog that falls inside the scaffold definition, method claims can still capture clinical use even when marketing or dosing language mirrors claimed regimens.
5) What is the most common attack route to invalidate patents like AU2006249245?
The most frequent invalidity arguments focus on anticipation, obviousness, and enablement across the full claimed range.
References (APA)
[1] IP Australia. Patent search entry for AU2006249245. https://www.ipaustralia.gov.au (accessed via IP Australia patent publication database).
[2] WIPO. PatentScope record for the PCT application family corresponding to AU2006249245. https://patentscope.wipo.int/.
